Search form

Ingelheim/Germany, and Aurora, CO /USA 13 November 2012 – Boehringer Ingelheim, a global leader in biopharmaceutical contract development and manufacture and BaroFold, Inc, a leader in high pressure protein refolding, today announced that they have entered into a non-exclusive technology and commercial license option agreement. Boehringer Ingelheim will acquire a laboratory-scale reactor of BaroFold’s Pressure Enabled Manufacturing Technology (PreEMTTM) that can also be qualified for GMP use. The technology will be installed at Boehringer Ingelheim’s microbial facility in Vienna, Austria and will be available for development of biopharmaceutical production processes.

“This partnership leverages the scale and success we have generated with our technology platform and we are very excited to license our high-pressure refolding technology to one of the world’s leading Biopharmaceutical and Contract Manufacturing Organizations," stated Kyle Lefkoff, Chairman of BaroFold. “Boehringer Ingelheim is a pioneer in biologic drug manufacturing and to extend our collaboration with them further enhances our ability to provide the global biotechnology arena with a novel refold technology,” stated Matthew Seefeldt, Ph.D., President and CSO at BaroFold.

“This collaboration builds upon the exciting work we have completed with BaroFold over the last 18 months and enhances our strategy to integrate the most innovative technologies for biologic manufacturing. We will be able to leverage BaroFold’s high pressure refold technology on a variety of proteins under development at our facility in Vienna,” stated Georg Klima, Executive Director Process Science Austria at Boehringer Ingelheim. “Innovation is what sets Boehringer Ingelheim apart from other biopharmaceutical and contract manufacturing companies and we look forward to realizing significant success with BaroFold’s technology.”

About PreEMT™

PreEMT™ is a patented technology that employs high pressure for the disaggregation and controlled refolding of recombinant proteins to their native structures at yields and efficiencies not achievable using existing technologies. PreEMT is transformative and practical for manufacturing processes and can substantially reduce the cost of manufacturing due to its increased yield and throughput at high protein concentrations. PreEMT is readily scalable and has been utilized for the cGMP production of phase 1 through phase 3 clinical material.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine. In 2011, Boehringer Ingelheim achieved net sales of about 13.2 billion euro.

Boehringer Ingelheim Biopharma Contract Manufacturing has now evolved into Boehringer Ingelheim BioXcellence. As a leading biopharmaceutical contract manufacturer with more than 35 years of experience – the company has brought 19 biopharmaceutical products to market. Boehringer Ingelheim BioXcellence offers tailor-made contract development and manufacturing services to the biopharmaceutical industry, providing the entire production technology chain from DNA to fill and finish under one roof at its facilities in Biberach (Germany), Vienna (Austria) and Fremont (USA).

Boehringer Ingelheim BioXcellence can secure product supply throughout the entire product lifecycle—transferring customer projects at any stage, delivering to almost any scale and thereby makes outsourcing easy. www.bioxcellence.com